Oncternal Announces Publication of Data from Phase 1 Trial of Cirmtuzumab in CLL in Cell Stem Cell

Oncternal Announces Publication of Data from Phase 1 Trial of Cirmtuzumab in CLL in Cell Stem Cell

June 1, 2018 ROR1 antibody found to inhibit the ability of chronic lymphocytic leukemia cells to self-renew and differentiate SAN DIEGO, June 1, 2018 /PRNewswire/ — Oncternal Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies for rare and common malignancies, today announced